Evangelos N. Symeonidis and Petros Sountoulides* Pages 1 - 13 ( 13 )
Lower urinary tract symptoms (LUTS) secondary to benign prostate obstruction (BPO), afflict a very large part of the population on a global scale. Urologists confront patients with a diversity of BPH-related symptoms in their daily practice. For years, the cornerstone of obstructive BPH treatment consisted of mostly medical and to a lesser extend surgical therapies. However and while medical treatment has come to a standstill, over the last decade, new minimally invasive surgical therapies (MISTs) have emerged, conferring several possible advantages over conventional transurethral resection of the prostate (TURP). MISTs have also demonstrated the ability to better respect and preserve sexual function, all while providing safety and minimal morbidity. Their long-term efficacy and durability over drug therapy remains debatable, as is the need for secondary procedures. In the present paper, we aim to offer a narrative summary of the available literature, thus providing an indirect comparative assessment of drugs and MISTs for obstructive LUTS.
LUTS, drugs, pharmacotherapy, minimally invasive therapies, mechanical devices, benign prostate obstruction, BPH.
1 st Department of Urology, Aristotle University of Thessaloniki, “G. Gennimatas” General Hospital, Thessaloniki, 1 st Department of Urology, Aristotle University of Thessaloniki, “G. Gennimatas” General Hospital, Thessaloniki